Results 1 to 10 of about 6,967 (165)

A Patient-Derived 3D Cyst Model of Polycystic Kidney Disease That Mimics Disease Development and Responds to Repurposing Candidates. [PDF]

Clin Transl Sci
ABSTRACT Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease. Its progressively expanding, fluid‐filled renal cysts eventually lead to end‐stage renal disease. Despite the relatively high prevalence, treatment options are currently limited to a single drug approved by the FDA and EMA.
Meyer A, Khalil B, Iljin M, Bange H, Price LS, Dyubankova N, van Westen GJP, van Vlijmen H, Peters DJM, Artursson P.   +9 more
europepmc   +2 more sources

Tolvaptan and urea in paediatric hyponatraemia.

Pediatric Nephrology, 2023
Abstract Background: The syndrome of inappropriate antidiuretic hormone (SIADH) is usually treated with fluid restriction. This can be challenging in patients with obligate fluid intake for nutrition or medication. Pharmaceutical treatment with tolvaptan and urea is available but minimal paediatric data are available. We review the efficacy and
Faidra Veligratli, Demitra Alexandrou, Sarit Shah, Rakesh Amin, Mehul Dattani, Hoong-Wei Gan, Adeola Famuboni, Camilo Lopez Garcia, Richard Trompeter, Detlef Bockenhauer   +9 more
openaire   +4 more sources

V2 Receptor Antagonist; Tolvaptan [PDF]

Electrolytes & Blood Pressure, 2011
Hyponatremia is the most common electrolyte disorder in hospitalized patients. Many studies documented that it was related to increased morbidity and mortality in patients with congestive heart failure, liver cirrhosis, and neurologic diseases. Although knowledge of hyponatremia has been cumulated, the optimal management of hyponatremia remains ...
Ho Jung Kim, Hyun Jong Shin, Joo Hark Yi
openaire   +3 more sources

Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease [PDF]

, 2016
The neurohypophysial hormone arginine vasopressin (AVP) acts by three distinct receptor subtypes: V1a, V1b, and V2. In the liver, AVP is involved in ureogenesis, glycogenolysis, neoglucogenesis and regeneration. No data exist about the presence of AVP in
Alpini, Gianfranco, Carpino, Guido, Franchitto, Antonio, Gaudio, Eugenio, Glaser, Shannon, Mancinelli, Romina, Olivero, Francesca, Onori, Paolo, Pannarale, Luigi, Sferra, Roberta, Venter, Julie, Vetuschi, Antonella   +11 more
core   +1 more source

Tolvaptan

South Asian Journal of Cancer, 2014
AbstractHyponatremia is a common and often under-recogonised clinical problem in oncologic practice. The recogonition of the cause of hyponatremia and initiation of appropriate and timely intervention can prevent morbidity and improve treatment tolerance. This drug review aims at discussing the currently approved oral vaptanagent Tolvaptan.
Bharath Rangarajan, Vineetha Binoy, Sachin Sharatchandra Hingmire, Vanita Noronha   +3 more
openaire   +3 more sources

ADPKD, Tolvaptan, and Nephrolithiasis Risk [PDF]

Clinical Journal of the American Society of Nephrology, 2020
Patients with autosomal dominant polycystic kidney disease (ADPKD) have a higher risk of nephrolithiasis ([1][1]). When using unenhanced computed tomography, calculi can be identified in up to 25% of patients with ADPKD ([2][2]).
Ewout J. Hoorn, Robert Zietse
openaire   +4 more sources

UNDULY ENHANCED RESPONSE TO TOLVAPTAN IN A WOMAN SHOWING SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION: AN INVESTIGATION OF POSSIBLE CAUSES [PDF]

, 2017
Objective: To investigate possible causes of an excessive response to tolvaptan in a woman with syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Lanzellotti, Davide, Martin, Marta, Padrini, Roberto, Panfili, Marco, Sartori, Geppo   +4 more
core   +1 more source

Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury [PDF]

Chemical Research in Toxicology, 2020
Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of liver injury in a small number of patients. Herein we describe the presence of tolvaptan- and tolvaptan-metabolite-responsive T cell clones within the peripheral circulation of patients with liver injury.
Andrew Gibson, Sean Hammond, Kanoot Jaruthamsophon, Sharin Roth, Merrie Mosedale, Dean J. Naisbitt   +5 more
openaire   +2 more sources

A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. [PDF]

, 2018
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the leading inheritable cause of end-stage renal disease (ESRD); however, the natural course of disease progression is heterogeneous between patients.
Bennett Wilton, Hayley, Cabrera, Maria-Cristina V, McEwan, Phil, O'Reilly, Karl, Ong, Albert CM, Robinson, Paul, Sandford, Richard, Scolari, Francesco, Walz, Gerd, Ørskov, Bjarne   +9 more
core   +5 more sources

Hyponatremia : Special Considerations in Older Patients [PDF]

, 2014
Acknowledgments Roy L.
Clarke, Jennifer M, Cumming, Kirsten, Myint, Phyo K, Soiza, Roy L, Wood, Karen M   +4 more
core   +2 more sources